Maximizing a therapeutic’s potential

Cell and gene therapy business

Clinigen US acquires and licenses therapeutics that are built upon strong scientific foundations. We have expertise in every phase of a product’s life cycle, from clinical trial development and FDA submission, through product expansion and global access.

Proleukin® (aldesleukin) is an example of how our forward thinking raised an underutilized therapeutic to new heights. This recombinant interleukin-2 (IL-2) stimulates the immune system, encouraging the growth of certain types of cells in the immune system that attack and kill cancer cells in patients with metastatic kidney cancer (mRCC) or metastatic melanoma (mM). It has a 30-year heritage of extensive clinical studies, pioneering basic immunology research.

We have the vision to successfully commercialize therapeutics that may currently be underappreciated.

Overcoming obstacles

The science behind Proleukin was unrefutably impressive. We saw the hope it brought to people. Some patients with mM and mRCC are alive more than 20 years after treatment.1-4,* Despite this, many healthcare professionals were not aware of best practices for using Proleukin, or which patients might benefit from treatment. We quickly worked to change that.

Today, patients, healthcare professionals, and scientific researchers are seeing the promise of Proleukin. We are partnering with companies that are studying its future potential—in combination or in sequence—with other anticancer agents in the oncology treatment landscape. Most recently, Clinigen was granted orphan drug status from the FDA for the potential role of aldesleukin in the treatment of amyotrophic lateral sclerosis (ALS). We are excited to be working with clinical partners that are studying aldesleukin as part of adoptive cellular therapy.


Moving immunotherapy science forward with Proleukin


Extending your reach

Clinigen US is also a gateway for companies that want to distribute medicines to patients outside the United States. Our established connections with pharmaceutical decision makers in other countries make it easy for you to get your medicines to the right patients, at the right time.

When a large pharmaceutical company was awaiting FDA approval for its oncology drug, their clinical team turned to Clinigen to provide early access in Europe. We implemented a Managed Access Program (MAP) that was in line with clinical trial protocols and compassionate drug use. This provided access to over 200 patients in 10 European countries.

Post FDA approval, our partner wanted to ensure mechanisms were in place to provide access for patients who did not qualify for MAP. We helped them gain access—and secure payment—in over 30 unlicensed countries, reaching more than 1,000 patients across Europe, Latin America, Asia, and Australia. We also helped manage their commercial launch in South Africa and provided thousands of drug doses for utilization in comparative clincal studies.

Our partners include:
  • Pharmaceutical and biotechnology companies
  • Academic institutions (ie, clinical researchers)

Moving immunotherapy science forward with Proleukin


*Objective response was seen in 16% of mM patients (6% complete and 10% partial responders) and in 15% of mRCC patients (7% complete and 8% partial responders).
References: 1. Proleukin [package insert]. Yardley, PA: Clinigen, Inc; 2019. 2. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000;6(suppl 1):S55-S57. 3. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am. 2000;6(suppl 1):S11-S14. 4. Data on file. Clinigen, Inc.


Interested in partnering with us?

Please use the form below so we can contact you to start the conversation about a business partnership.  Or, contact James Dewis at XXX-XXX-XXXX.



  1. All disclosures on your part are completely voluntary and our review of your submission neither creates nor implies a confidential, fiduciary, employment or contractual relationship. Clinigen US owes NO COMPENSATION, COMMISSION, OR ANY OTHER PAYMENT to you as a result of your submission.
  2. All information you are disclosing is nonconfidential and nonproprietary. Clinigen US shall not be liable for any disclosure of any information you submit.
  3. Clinigen US shall not be obligated to specify the reasons for any decision it makes regarding the submission or to reveal any past or present activities that relate to the submission.
  4. You will not challenge or object, or assist any third party to challenge or object, to any use Clinigen US may make of your submission and any information contained therein for any purpose, and you expressly waive any rights you may have to do so.
  5. You have read, understand, and agree to the Clinigen US website Legal Notice and Privacy Policy.

I certify that I have read and understood the above, and by selecting Accept and submission of this form indicates my intention to be legally bound to the above terms.

Contact information

Information with an asterisk (*) is required.

First name*
Last name*
Phone number*
Confirm email*
Organization name*
Street address*
Street address line 2
Zip code*
Brief opportunity description*

If you see this, leave this form field blank and invest in CSS support!